Power Deposition on Tokamak Plasma-Facing Components

The SMARDDA software library is used to model plasma interaction with complex engineered surfaces. A simple flux-tube model of power deposition necessitates the following of magnetic fieldlines until they meet geometry taken from a CAD (Computer Aided Design) database. Application is made to 1) models of ITER tokamak limiter geometry and 2) MASTU tokamak divertor designs, illustrating the accuracy and effectiveness of SMARDDA, even in the presence of significant nonaxisymmetric ripple field. SMARDDA's ability to exchange data with CAD databases and its speed of execution also give it the potential for use directly in the design of tokamak plasma facing components.Comment: 13 pages, 20 figure

Ranking the importance of nuclear reactions for activation and transmutation events

Pathways-reduced analysis is one of the techniques used by the Fispact-II nuclear activation and transmutation software to study the sensitivity of the computed inventories to uncertainties in reaction cross-sections. Although deciding which pathways are most important is very helpful in for example determining which nuclear data would benefit from further refinement, pathways-reduced analysis need not necessarily define the most critical reaction, since one reaction may contribute to several different pathways. This work examines three different techniques for ranking reactions in their order of importance in determining the final inventory, comparing the pathways based metric (PBM), the direct method and one based on the Pearson correlation coefficient. Reasons why the PBM is to be preferred are presented.Comment: 30 pages, 10 figure

Wavenumber Selection of Convection Rolls in a Box

The dynamics of two‐dimensional Rayleigh–Bénard convection rolls are studied in a finite layer with no‐slip, fixed temperature upper and lower boundaries and no‐slip insulating side walls. The dominant mechanism controlling the number of rolls seen in the layer is an instability concentrated near the side walls. This mechanism significantly narrows the band of stable wavenumbers although it can take a time comparable to the long (horizontal) diffusion time scale to operate

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication